Search Results
Your search for 3 matches 16011 pages
Showing 201 - 250Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China
Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherapy produced high pathologic response rates in patients in China with HER2-positive locally advanced...
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...
Case 3: BRCA-Mutated Metastatic Prostate Cancer
This is Part 3 of Integrating Targeted Therapies in mHSPC: A Changing Treatment Landscape, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Atish D. Choudhury, MD, PhD, Karen Autio, MD, MSc, and Elizabeth M. Wulff, MD, discuss the...
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigdomide-Based Regimen Improves...
Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer
In a cohort study of patients with nonmetastatic colorectal cancer, treatment delays were associated with a higher risk of metastasis, with the magnitude differing by treatment pathway. Nguyen et al published the findings in JAMA Network Open. “These results suggest that pathway-specific thresholds ...
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant
Researchers have found that with new treatment regimens now available for functional high-risk multiple myeloma, clinicians should use different criteria for identifying patients with poor odds of survival. These findings were published by Ravi et al in the journal Cancer. Functional high-risk...
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
A review of the scientific literature on the impact of environmental factors on the health of pediatric cancer survivors by Omar Shakeel, MD, Assistant Professor in the Department of Pediatrics, Division of Hematology-Oncology at Baylor College of Medicine and Head of the Long-Term Survivor Clinic ...
Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception
A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to phase I clinical trial results published by Haidar et al in Cancer Discovery....
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–associated antigen 4] plus regular interval durvalumab [anti–PD-L1]) with or without lenvatinib...
Expert Dermatologists Outperform AI Foundation Models in Real-World Skin Cancer Diagnosis
According to a diagnostic study reported in JAMA Dermatology by Anriot et al, a modern artificial intelligence (AI) foundation model outperformed less experienced clinicians but did not match the diagnostic performance of expert dermatologists when tested under realistic clinical conditions. The...
Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer
New results from an Alliance Foundation Trials (AFT) study reveal that a simple weekly electronic symptom check-in with the care team significantly improves the quality of life for individuals undergoing treatment for advanced cancer. Researchers found that the biggest improvements were seen among...
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous...
ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance resulted in more toxicity with no survival benefit from continuing treatment until disease progression compared with stopping after 2 years. Results from the...
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
As reported in The Lancet by Xiong et al, an interim analysis of a Chinese phase III trial (OptiTROP-Lung05) has shown that the addition of sacituzumab tirumotecan (a trophoblast cell–surface antigen 2–targeting antibody-drug conjugate) to pembrolizumab significantly prolonged progression-free...
KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstract...
Radiotherapy Dose Escalation With Intraoperative Radiotherapy vs Surgery Alone in Glioblastoma
In a phase III trial (INTRAGO-II) reported in The Lancet Oncology, Giordano et al found that the addition of intraoperative radiotherapy to surgery did not improve outcomes in patients with newly diagnosed glioblastoma. Study Details The open-label trial enrolled 298 patients (full-analysis set)...
Stage III HER2-Negative Breast Cancer With HRD: Standard Chemotherapy Plus Olaparib
In a European phase III trial (SUBITO) reported in The Lancet Oncology, Seefat et al found that intensified alkylating chemotherapy with autologous stem cell rescue (IACT) provided no overall survival advantage vs standard chemotherapy followed by olaparib in patients with stage IIIA-C...
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma. Study...
Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy
As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study (RAPCHEM: BOOG 2010–03) indicated that tailoring postoperative locoregional radiotherapy based on nodal response to primary chemotherapy was associated with maintenance of a low locoregional ...
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
On July 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with the NECTIN4-directed antibody-drug conjugate enfortumab vedotin-ejfv (Padcev), as neoadjuvant...
Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Francolini et al, an unplanned long-term analysis of overall survival in the Italian phase II ARTO trial showed a survival benefit with the addition of metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to abiraterone acetate and...
Head and Neck Cancer: Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin
In the long-term follow-up of a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced ...
Advanced Gastric or GEJ Cancer: First-Line Disitamab Vedotin, Tislelizumab, and S-1
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Li et al found that the first-line combination of disitamab vedotin, tislelizumab, and S-1 was associated with high activity in patients with HER2-overexpressing advanced gastric/gastroesophageal junction (GEJ)...
Case 3: Metastatic Hepatocellular Carcinoma After Failure of First-Line Immunotherapy
This is Part 3 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss management of...
Case 2: Metastatic Hepatocellular Carcinoma
This is Part 2 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss the management of...
Case 1: Liver-Limited Hepatocellular Carcinoma
This is Part 1 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss treatment...
Case 3: Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
This is Part 3 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss second-line treatment of extensive-stage...
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
The addition of radiotherapy to the S-1 plus oxaliplatin (SOX) chemotherapy regimen did not improve disease-free or overall survival in patients with pathologic T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy (ie, R0 resection with D2 lymphadenectomy), based on a phase...
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax was highly active in patients with relapsed or refractory acute myeloid leukemia (AML). Revumenib is an...
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia called blastic plasmacytoid dendritic cell neoplasm (BPDCN) may eventually develop resistance to tagraxofusp-ezrs, the first U.S. Food and Drug Administration–approved...
Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab induced clinically meaningful antitumor activity and showed a favorable safety profile in patients with advanced NRG1-positive cholangiocarcinoma, according to findings from the phase II eNRGy trial published in the Journal of Clinical Oncology. “Second-line chemotherapy is only...
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
In the long-term follow-up to a phase II study published in The New England Journal of Medicine, Ruella et al found that a single infusion of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 (now called tisagenlecleucel) produced decade-long remissions in a subset of patients ...
FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant
On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative...
Single-Fraction SBRT in Localized Prostate Cancer
In a phase I/II trial reported in JAMA Oncology, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse–free survival rate in patients with localized prostate cancer. Study Details In the trial, 43 patients with...
Case 3: Toxicity Management in ER-Positive Breast Cancer
This is Part 3 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Long-Term Outcomes With SABR in Primary Renal Cell Carcinoma
As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma who did not undergo ...
MRI-Guided Radiotherapy in High-Grade Glioma
In a single-center Canadian phase II trial (UNITED) reported in The Lancet Oncology, Detsky et al found that magnetic resonance imaging (MRI)-guided adaptation of radiotherapy allowed margin de-escalation and resulted in a low rate of marginal failure in patients with high-grade glioma. Study...
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...
Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal
Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a...
Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer
In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers. Study Details The analysis included studies of CD3-based...
AACR Cancer Disparities Progress Report: Trends Show Mortality Rates Improve But Inequity in Care Remains
On June 24, the American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026.1 As in past years, the report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since...
Doublet in Low-Risk Gestational Trophoblastic Tumors
In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors. Study Details In the multicenter study, 27 patients with low-risk gestational...
Ultra–High-Risk LBCL: Does High-Dose Methotrexate Reduce Rates of CNS Relapse?
In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) relapse in patients with ultra–high-risk large B-cell lymphoma (LBCL). Study Details The analysis...
FDA Approves Capivasertib Plus Abiraterone With ADT/Prednisone in Patients With mHSPC
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (also referred to as metastatic hormone-sensitive...
Update to ASCO Guideline on Advanced NSCLC Without Driver Alterations Adds Retifanlimab to Treatment Options
ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations.1 The update, which includes a new recommendation regarding the PD-1 inhibitor retifanlimab-dlwr and chemotherapy, follows a recent full update to the guideline...
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer
Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Elisrasib was ...
SENOMAC Trial: Omission of Completion Axillary Dissection Is Oncologically Safe in Expanded Breast Cancer Population
The international non-inferiority SENOMAC trial has confirmed that omitting completion axillary lymph node dissection (ALND) is oncologically safe (ie, a less intensive approach does not compromise outcomes) and substantially reduces patient-reported arm morbidity in patients with one or two...
TAPUR Marks a Decade of Innovation
In 2013, during the ASCO Annual Meeting, Richard L. Schilsky, MD, FACP, FSCT, FASCO, then ASCO’s Chief Medical Officer, presented a bold clinical trial concept during an educational session on the challenges of delivering precision medicine services in an oncology community care setting. The idea...
Talquetamab Combinations in Relapsed or Refractory Myeloma
In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...
Advanced Breast Cancer: Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...
